Castle Biosciences Inc (CSTL)
$28.1
Performance
- $28.06$30.47$28.10
0.14%
Downside
Day's Volatility :7.91%
Upside
7.78%
- $16.97$35.84$28.10
39.63%
Downside
52 Weeks Volatility :52.66%
Upside
21.6%
Returns
| Period | Castle Biosciences Inc | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | 0.5% | -7.2% | 0.0% |
6 Months | 15.92% | -3.1% | 0.0% |
1 Year | 43.08% | 10.6% | 0.0% |
3 Years | -46.37% | 6.1% | -25.6% |
Highlights
Market Capitalization | 863.5M |
Book Value | $15.77 |
Earnings Per Share (EPS) | 0.21 |
PE Ratio | 146.81 |
Wall Street Target Price | 41.556 |
Profit Margin | 1.95% |
Operating Margin TTM | 5.92% |
Return On Assets TTM | -0.14% |
Return On Equity TTM | 1.47% |
Revenue TTM | 311.9M |
Revenue Per Share TTM | 11.34 |
Quarterly Revenue Growth YOY | 39.5% |
Gross Profit TTM | 105.0M |
EBITDA | 12.4M |
Diluted Eps TTM | 0.21 |
Quarterly Earnings Growth YOY | -0.93 |
EPS Estimate Current Year | 0.36 |
EPS Estimate Next Year | -1.91 |
EPS Estimate Current Quarter | -0.06 |
EPS Estimate Next Quarter | -0.76 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 47.88%
Technicals Summary
Sell
Neutral
Buy
Castle Biosciences Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Castle Biosciences Inc | -15.0% | 15.92% | 43.08% | -46.37% | -2.46% |
 Idexx Laboratories, Inc. | -8.5% | -22.55% | -9.23% | -32.98% | 61.56% |
 Agilent Technologies Inc. | -7.53% | -17.61% | 12.3% | -21.34% | 63.04% |
 Thermo Fisher Scientific, Inc. | -14.38% | -13.81% | 10.0% | -19.49% | 70.46% |
 Danaher Corp. | -15.25% | -13.28% | 10.93% | -25.57% | 64.37% |
 Iqvia Holdings Inc. | -17.62% | -16.65% | -5.91% | -27.14% | 35.58% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Castle Biosciences Inc | 146.81 | 146.81 | NA | 0.36 | 0.01 | 0.0 | NA | 15.77 |
Idexx Laboratories, Inc. | 41.49 | 41.49 | 4.53 | 10.78 | 0.59 | 0.23 | NA | 19.72 |
Agilent Technologies Inc. | 27.09 | 27.09 | 2.81 | 5.24 | 0.25 | 0.08 | 0.01 | 20.53 |
Thermo Fisher Scientific, Inc. | 34.02 | 34.02 | 2.06 | 21.7 | 0.13 | 0.05 | 0.0 | 128.08 |
Danaher Corp. | 45.68 | 45.68 | 2.84 | 7.51 | 0.08 | 0.04 | 0.0 | 71.03 |
Iqvia Holdings Inc. | 26.65 | 26.65 | 1.05 | 11.14 | 0.22 | 0.05 | NA | 38.37 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Castle Biosciences Inc | Buy | $863.5M | -2.46% | 146.81 | 1.95% |
Idexx Laboratories, Inc. | Buy | $34.7B | 61.56% | 41.49 | 22.53% |
Agilent Technologies Inc. | Buy | $37.4B | 63.04% | 27.09 | 21.75% |
Thermo Fisher Scientific, Inc. | Buy | $203.9B | 70.46% | 34.02 | 14.48% |
Danaher Corp. | Buy | $172.9B | 64.37% | 45.68 | 16.39% |
Iqvia Holdings Inc. | Buy | $36.8B | 35.58% | 26.65 | 9.17% |
Insights on Castle Biosciences Inc
Decreasing Revenue
Revenue is down for the last 2 quarters, 87.00M → 85.78M (in $), with an average decrease of 1.4% per quarter
Decreasing Net Profit
Netprofit is down for the last 2 quarters, 8.92M → 2.26M (in $), with an average decrease of 74.6% per quarter
Vs TMO
In the last 3 years, Castle Biosciences Inc has experienced a drawdown of -46.4%, however Thermo Fisher Scientific, Inc. resisted the overall trend and outperformed by 25.1%
Institutional Holdings
BlackRock Inc
10.87%Wasatch Advisors LP
8.31%Vanguard Group Inc
5.63%Principal Financial Group Inc
5.49%Bellevue Group AG
4.35%Portolan Capital Management, LLC
4.32%
Company Information
castle biosciences, inc. specializes in diagnostic tests for cancers. founded in 2008, the company goal has been to help advance the care for cancers through objective testing. our team works with outstanding members of the oncology community throughout the discovery, development and utilization of these tests. currently, castle biosciences has tests to help doctors treat cutaneous melanoma, uveal melanoma, esophageal adenocarcinoma, mesothelioma and glioma. we have active research programs in rectal cancer and soft tissue sarcoma, and anticipate tests for these and other under-served cancers to be available in the near future please visit us at www.castlebiosciences.com for more information on our company and products.
Organization | Castle Biosciences Inc |
Employees | 710 |
CEO | Mr. Derek J. Maetzold |
Industry | Health Technology |
Discover More
Cactus Acquisition Corp 1 Ltd
$28.10
-8.86%
Rigel Resource Acquisition Corp
$28.10
-8.86%
Fortune Rise Acquisition Corp
$28.10
-8.86%
P.a.m. Transportation Svcs
$28.10
-8.86%
Onyx Acquisition Co. I
$28.10
-8.86%
Blockchain Coinvestors Acquisition Corp.
$28.10
-8.86%
Perception Capital Corp Iv
$28.10
-8.86%
Bny Mellon Ultra Short Income Etf
$28.10
-8.86%
Evgo Inc Cl A
$28.10
-8.86%